OTCMKTS:CRXLY - Crucell Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Crucell NV is a Netherlands-based biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. The Company's product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. It focuses on the paediatric, travel and endemic, and respiratory fields. Its core product portfolio includes Quinvaxem, a liquid pentavalent vaccine against five important childhood diseases; Hepavax-Gene, a hepatitis B vaccine; Epaxal, an aluminum-free hepatitis A vaccine; Vivotif and Dukoral, oral vaccines against typhoid and cholera; and Inflexal V, a virosomal adjuvanted vaccine against influenza. It has offices in the Netherlands, China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States and Vietnam. Receive CRXLY News and Ratings via Email Sign-up to receive the latest news and ratings for CRXLY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry N/A Sub-IndustryN/A SectorN/A Current SymbolOTCMKTS:CRXLY Previous SymbolNASDAQ:CRXL CUSIPN/A WebN/A Phone+31-71-5199100 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable Crucell (OTCMKTS:CRXLY) Frequently Asked Questions What is Crucell's stock symbol? Crucell trades on the OTCMKTS under the ticker symbol "CRXLY." Has Crucell been receiving favorable news coverage? Media headlines about CRXLY stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crucell earned a news impact score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. How do I buy shares of Crucell? Shares of CRXLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Crucell? Crucell's mailing address is Archimedesweg 4, LEIDEN, 2333CN, Netherlands. The biopharmaceutical company can be reached via phone at +31-71-5199100. MarketBeat Community Rating for Crucell (OTCMKTS CRXLY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 39 (Vote Outperform)Underperform Votes: 37 (Vote Underperform)Total Votes: 76MarketBeat's community ratings are surveys of what our community members think about Crucell and other stocks. Vote "Outperform" if you believe CRXLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRXLY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/19/2018 by MarketBeat.com StaffFeatured Article: Why is insider trading harmful?